TAK vs. NUTX
TAK (Takeda Pharmaceutical Company Limited) and NUTX (Nutex Health Inc) are both stocks. Both are in the Healthcare sector — TAK in Drug Manufacturers - Specialty & Generic, NUTX in Health Information Services. Over the past 3 years, TAK returned 3.51%/yr vs 29.42%/yr for NUTX. At a 0.05 correlation, their price movements are largely independent.
Performance
TAK vs. NUTX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, TAK achieves a 1.60% return, which is significantly higher than NUTX's -10.56% return.
TAK
- 1D
- 2.39%
- 1M
- -2.52%
- YTD
- 1.60%
- 6M
- 2.46%
- 1Y
- 10.03%
- 3Y*
- 3.51%
- 5Y*
- 2.25%
- 10Y*
- 0.88%
NUTX
- 1D
- -1.96%
- 1M
- 23.82%
- YTD
- -10.56%
- 6M
- -12.02%
- 1Y
- 26.00%
- 3Y*
- 29.42%
- 5Y*
- —
- 10Y*
- —
TAK vs. NUTX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
TAK Takeda Pharmaceutical Company Limited | 1.60% | 23.18% | -3.12% | -4.87% | 10.29% |
NUTX Nutex Health Inc | -10.56% | 419.47% | 17.37% | -90.53% | -81.82% |
Correlation
The correlation between TAK and NUTX is 0.00, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.00 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.03 |
Correlation (All Time) Calculated using the full available price history since Apr 4, 2022 | 0.05 |
Fundamentals
TAK:
¥61.03
NUTX:
$19.08
TAK:
41.95
NUTX:
7.72
TAK:
3.71
NUTX:
0.06
TAK:
1.78
NUTX:
0.85
TAK:
¥4.55T
NUTX:
$879.95M
TAK:
¥2.66T
NUTX:
$417.67M
TAK:
¥1.43T
NUTX:
$275.94M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
TAK vs. NUTX — Risk / Return Rank
TAK
NUTX
TAK vs. NUTX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Takeda Pharmaceutical Company Limited (TAK) and Nutex Health Inc (NUTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| TAK | NUTX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.21 | ||
| Sortino ratioReturn per unit of downside risk | -0.27 | ||
| Omega ratioGain probability vs. loss probability | 1.10 | 1.13 | -0.03 |
| Calmar ratioReturn relative to maximum drawdown | 0.50 | 0.48 | +0.02 |
| Martin ratioReturn relative to average drawdown | 1.35 | 0.84 | +0.51 |
Loading charts...
Drawdowns
TAK vs. NUTX - Drawdown Comparison
The maximum TAK drawdown since its inception was -54.25%, smaller than the maximum NUTX drawdown of -99.93%. Use the drawdown chart below to compare losses from any high point for TAK and NUTX.
Loading charts...
Drawdown Indicators
| TAK | NUTX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -54.25% | -99.93% | +45.68% |
Max Drawdown (1Y)Largest decline over 1 year | -20.05% | -54.32% | +34.27% |
Max Drawdown (3Y)Largest decline over 3 years | -20.05% | -93.95% | +73.90% |
Max Drawdown (5Y)Largest decline over 5 years | -24.50% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -54.25% | — | — |
Current DrawdownCurrent decline from peak | -30.30% | -97.55% | +67.25% |
Average DrawdownAverage peak-to-trough decline | -23.27% | -97.19% | +73.92% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.47% | 31.05% | -23.58% |
Volatility
TAK vs. NUTX - Volatility Comparison
The current volatility for Takeda Pharmaceutical Company Limited (TAK) is 7.92%, while Nutex Health Inc (NUTX) has a volatility of 16.24%. This indicates that TAK experiences smaller price fluctuations and is considered to be less risky than NUTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| TAK | NUTX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.92% | 16.24% | -8.32% |
Volatility (6M)Calculated over the trailing 6-month period | 15.33% | 62.35% | -47.02% |
Volatility (1Y)Calculated over the trailing 1-year period | 20.73% | 93.22% | -72.49% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 19.58% | 191.37% | -171.79% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 23.04% | 191.37% | -168.33% |
Dividends
TAK vs. NUTX - Dividend Comparison
TAK's dividend yield for the trailing twelve months is around 2.03%, while NUTX has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NUTX Nutex Health Inc | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
TAK Takeda Pharmaceutical Company Limited | 2.03% | 4.24% | 4.67% | 4.41% | 4.23% | 2.98% | 2.30% | 4.20% | 4.77% | 2.81% | 3.99% | 2.92% |
Financials
TAK vs. NUTX - Financials Comparison
This section allows you to compare key financial metrics between Takeda Pharmaceutical Company Limited and Nutex Health Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
TAK vs. NUTX - Profitability Comparison
TAK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Takeda Pharmaceutical Company Limited reported a gross profit of 543.81B and revenue of 1.11T. Therefore, the gross margin over that period was 48.8%.
NUTX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Nutex Health Inc reported a gross profit of 91.73M and revenue of 216.49M. Therefore, the gross margin over that period was 42.4%.
TAK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Takeda Pharmaceutical Company Limited reported an operating income of 47.54B and revenue of 1.11T, resulting in an operating margin of 4.3%.
NUTX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Nutex Health Inc reported an operating income of 81.27M and revenue of 216.49M, resulting in an operating margin of 37.5%.
TAK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Takeda Pharmaceutical Company Limited reported a net income of -24.77B and revenue of 1.11T, resulting in a net margin of -2.2%.
NUTX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Nutex Health Inc reported a net income of 46.81M and revenue of 216.49M, resulting in a net margin of 21.6%.
Frequently Asked Questions
TAK and NUTX have a correlation of 0.00, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NUTX has higher volatility (16.24%) compared to TAK (7.92%). In terms of maximum drawdown, TAK dropped -54.25% vs NUTX's -99.93%.
TAK currently has the higher Sharpe Ratio (0.49 vs 0.28), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for TAK and NUTX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer